We provide you with 20 years of free, institutional-grade data for CHRS stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CHRS. Explore the full financial landscape of CHRS stock.
| Reported Date | CIK | Ticker | Type |
|---|
Coherus BioSciences, Inc(NASDAQ:CHRS) 
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline...
Website: http://www.coherus.com
Founded: 2010
Full Time Employees: 306
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about CHRS stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.